Breaking Investor news on the marijuana space.
TheSeedInvestor
Invest in the Emerging Marijuana Industry
There will be a sudden wave of "Marijuana Millionaires" in 2017 - will you be one?

 
13x13x1 READ MORE
How To Invest in the Emerging Marijuana Market.
 
LEARN MORE
Dear Seed Investor, 

We have some breaking news for you! 

InMed Pharmaceuticals (CSE: IN; OTCQB: IMLFF) just released a major patent announcement today that could change the face of the medical marijuana industry. 

Today we saw a company take a major step towards solving a major inefficiency problem in the marijuana industry, which could also put billions of dollars into play. 

InMed is now poised to do to cannabis medicine what Ely Lilly did back in the early 1980s to the then insulin manufacturing industry.

Namely, transforming an entire industry through biosynthetics and creating a billion dollar plus business.

This is massive news for investors who want to get in early on a company poised for stratospheric growth. Right now InMed is under valued and under the radar, but with this announcement it might not stay that way for long. 

Read the Full Story at The Seed Investor 

High Profits, 

The Seed Investor
Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor. 

 
32x32x1   32x32x2   32x32x3
TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260
info@theseedinvestor.com
 
©2018, All Rights Reserved  |  Unsubscribe   |   View this in Browser

To keep receiving emails from us, please add us to your address book.